Selection bias, phase II trials, and the FDA accelerated approval process.
Publication
, Journal Article
George, SL
Published in: J Natl Cancer Inst
September 17, 2003
Duke Scholars
Published In
J Natl Cancer Inst
DOI
EISSN
1460-2105
Publication Date
September 17, 2003
Volume
95
Issue
18
Start / End Page
1351 / 1352
Location
United States
Related Subject Headings
- United States Food and Drug Administration
- United States
- Treatment Outcome
- Selection Bias
- Quinazolines
- Oncology & Carcinogenesis
- Neoplasms
- Lung Neoplasms
- Humans
- Gefitinib
Citation
APA
Chicago
ICMJE
MLA
NLM
George, S. L. (2003). Selection bias, phase II trials, and the FDA accelerated approval process. J Natl Cancer Inst, 95(18), 1351–1352. https://doi.org/10.1093/jnci/djg070
George, Stephen L. “Selection bias, phase II trials, and the FDA accelerated approval process.” J Natl Cancer Inst 95, no. 18 (September 17, 2003): 1351–52. https://doi.org/10.1093/jnci/djg070.
George SL. Selection bias, phase II trials, and the FDA accelerated approval process. J Natl Cancer Inst. 2003 Sep 17;95(18):1351–2.
George, Stephen L. “Selection bias, phase II trials, and the FDA accelerated approval process.” J Natl Cancer Inst, vol. 95, no. 18, Sept. 2003, pp. 1351–52. Pubmed, doi:10.1093/jnci/djg070.
George SL. Selection bias, phase II trials, and the FDA accelerated approval process. J Natl Cancer Inst. 2003 Sep 17;95(18):1351–1352.
Published In
J Natl Cancer Inst
DOI
EISSN
1460-2105
Publication Date
September 17, 2003
Volume
95
Issue
18
Start / End Page
1351 / 1352
Location
United States
Related Subject Headings
- United States Food and Drug Administration
- United States
- Treatment Outcome
- Selection Bias
- Quinazolines
- Oncology & Carcinogenesis
- Neoplasms
- Lung Neoplasms
- Humans
- Gefitinib